A mutation-led search for novel functional domains in MeCP2

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Rett syndrome (RTT) is a neurodevelopmental disorder primarily caused by mutations in the methyl CpG-binding protein 2 (MECP2) gene.
• Most known RTT-causing mutations affect critical MeCP2 domains involved in DNA binding or co-repressor interaction.
• However, some mutations, including C-terminal truncations, occur outside these well-characterized functional regions.

Purpose of the Study:

• To investigate the molecular consequences of four 'non-canonical' MeCP2 mutations in RTT.
• To determine if these mutations affect previously identified MeCP2 functional domains or reveal new ones.
• To explore potential therapeutic avenues for RTT based on mutation impact.

Main Methods:

• Analysis of four non-canonical MeCP2 mutations in cultured neurons and mouse models.
• Assessment of MeCP2 protein levels and stability.
• Evaluation of MeCP2 interaction with transcriptional co-repressor complexes.

Main Results:

• The studied mutations partially or strongly depleted MeCP2 protein levels.
• Some mutations interfered with the recruitment of transcriptional co-repressors.
• These effects indicate that non-canonical mutations impact known MeCP2 functional domains.

Conclusions:

• Non-canonical MeCP2 mutations do not represent novel molecular causes of Rett syndrome.
• These mutations affect the function of established MeCP2 domains.
• Stabilizing truncated MeCP2 proteins may offer a therapeutic strategy for RTT.